Trial · NCT05861050
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
NCT05861050, Phase 1, Phase 2, Recruiting, City of Hope Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma. Trials, record NCT05861050. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05861050
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
- NCT number
- NCT05861050
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 50 participants, estimated
- Lead sponsor
- City of Hope Medical Center
- Conditions
- Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma
- Interventions
- Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Glofitamab, Lenalidomide, Obinutuzumab, Positron Emission Tomography, Venetoclax
- First posted
- 2023-05-16
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression free survival (PFS) | From first dose of combination lenalidomide, venetoclax, and glofitamab to the occurrence of definitive disease progression or death from any cause, assessed up to 24 months | |
| Primary | Incidence of dose limiting toxicity | Up to 63 days after initiation of venetoclax | Adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. |
| Secondary | Incidence of adverse events of special interest | From baseline up until 30 days after last dose of study drug | Adverse events of special interest including neurotoxicity, cytopenias, and infections are graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5. Cytokine release syndrome is graded according to American Society for Transplantation and Cellular Therapy criteria. |
| Secondary | Median (or mean) PFS | From the first dose of the combination of lenalidomide, venetoclax, and glofitamab to the occurrence of definitive disease progression or death from any cause, whichever comes first, assessed up to 5 years | |
| Secondary | Best overall response | Until disease progression or at 1 year after initiating therapy, whichever is sooner | Determined by revised Lugano 2016 criteria. Includes complete response and partial response. |
| Secondary | Minimal residual disease status | At the end of 12 cycles of treatment (each cycle is 28 days) | |
| Secondary | Duration of response | From the time of initial response until disease progression or death due to any cause, whichever occurs first, assessed up to 2 years |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA033572 | Cancer Center Support Grant | CARPTEN, JOHN D. | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE | NATIONAL CANCER INSTITUTE | 1985 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05861050
GET https://conductscience.org/api/trials/v1/NCT05861050/registered